Immuneering Corp (IMRX)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss from marketable securities | - | |||
| Other income, net | - | |||
| Research and development | 10,454,160 | |||
| General and administrative | 4,296,417 | |||
| Amortization of intangible asset | 7,317 | |||
| Total operating expenses | 14,757,894 | |||
| Loss from operations | -14,757,894 | |||
| Interest income | 324,013 | |||
| Net loss | -14,433,881 | |||
| Comprehensive loss | -14,433,881 | |||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.4 | |||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.4 | |||
| Weighted-average common shares outstanding, basic (in shares) | 35,985,878 | |||
| Weighted-average common shares outstanding, diluted (in shares) | 35,985,878 | |||